Tenecteplase in Stroke Patients Between 4 and 24 Hours

2019-01-03 08:55:16 | BioPortfolio

Published on BioPortfolio: 2019-01-03T08:55:16-0500

Clinical Trials [128 Associated Clinical Trials listed on BioPortfolio]

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

The principle research question is: in patients with acute ischaemic stroke eligible for IV thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as ...

Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial

The general aim of this study is to compare the efficacy and safety of tenecteplase to standard treatment during cardiopulmonary resuscitation in patients suffering from out-of-hospital ca...

Tenecteplase in Wake-up Ischaemic Stroke Trial

Stroke is a leading causes of death and disability. At least 20% of strokes occur during sleep, so- called 'wake up stroke'. Thrombolysis with the clot-busting drug alteplase is effective ...

Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion

Proximal Middle Cerebral Artery (MCA) occlusions constitute the most severe stroke. Intra-venous thrombolysis with rt-PA within the first 4,5 hours is the only proven effective treatment (...

Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

Patients presenting to the emergency department with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be assessed for maj...

PubMed Articles [963 Associated PubMed Articles listed on BioPortfolio]

Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.

Background and Purpose- Tenecteplase represents a promising alternative to alteplase as thrombolytic treatment in acute ischemic stroke. There are limited data on tenecteplase 0.4 mg/kg in patients wi...

Tenecteplase utility in acute ischemic stroke patients: A clinical review of current evidence.

Acute ischemic stroke is a leading cause of disability in the United States. Treatment is aimed at reducing impact of cerebral clot burden and life-long disability. Traditional fibrinolytic treatment ...

Stabilizing osmolytes' effects on the structure, stability and function of tc-tenecteplase: A one peptide bond digested form of tenecteplase.

Organic osmolytes, as major cellular compounds, cause protein stabilization in the native form. In the present study, the possible chaperone effects of the three naturally occurring osmolytes on the t...

Comorbid cancer and use of thrombolysis in acute pulmonary embolism.

Guidelines suggest the use of thrombolytic therapy for acute pulmonary embolism (PE) patients with hypotension who are not at high-risk of bleeding. Data describing the use of thrombolysis in patients...

Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction.

Intravenous thrombolysis (IVT) is considered to be the standard reperfusion therapy for acute ischemic stroke (AIS), but its application is limited by high risk of hemorrhagic transformation (HT) afte...

Medical and Biotech [MESH] Definitions

Procedures to cause the disintegration of THROMBI by physical interventions.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm.

More From BioPortfolio on "Tenecteplase in Stroke Patients Between 4 and 24 Hours"

Quick Search


Searches Linking to this Trial